LoginSign Up
Rheostat Therapeutics

Rheostat Therapeutics

Rheostat, located at LabCentral, Cambridge, Massachusetts is a biotech company developing treatments for neurodegenerative diseases by targeting mitophagy and autophagy pathways.

Rheostat is developing treatments for neurodegenerative disease by modulation of mitophagy and autophagy. Rheostat is focusing on molecular pathways involved in clearance of toxic components such as damaged organelles or aggregated proteins because mutations in these pathways cause many neurodegenerative diseases associated with cognitive impairment. Rheostat aims to use knowledge about these clearance pathways to find and develop small molecules that can restore cellular balance for the treatment of neurodegenerative and rare diseases.

Rheostat Therapeutics has funding from Dementia Discovery Fund.

Timeline

People

Name
Role
Related Golden topics

Christophe J. Echeverri

Interim Head of Operations

Darby R. Schmidt

Senior Director, Head of Chemistry

J. Stefan Kaczmarek

Scientific Director

Joshua Resnick

Chair and CEO

Magdalene Moran

Principle Investigator

Nathaniel Tyler Blair

Associate Director of Biology

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References